TOPICS
Email Deliverability for Biotech & Pharma
DIRECT ANSWER
Email deliverability is the rate at which sent emails actually reach a recipient's inbox — not just avoid a bounce, but clear spam filters and land where they're read. It depends on sender authentication (SPF, DKIM, DMARC), list hygiene, engagement history, and infrastructure reputation. Industry inbox placement benchmarks sit around 85–90% for well-maintained senders. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What email deliverability means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
The Technical Foundation: Authentication and Reputation
Three DNS-based standards form the technical floor of deliverability. SPF (Sender Policy Framework) specifies which mail servers are authorized to send on your domain's behalf. DKIM (DomainKeys Identified Mail) cryptographically signs each message so receiving servers can verify it wasn't tampered with in transit. DMARC (Domain-based Message Authentication, Reporting & Conformance) tells receiving servers what to do when SPF or DKIM fails — quarantine, reject, or monitor — and sends aggregate reports back to the sender.
Beyond authentication, sending reputation accumulates over time at the IP and domain level. Mailbox providers like Google, Microsoft, and Yahoo use engagement signals — open rate, click rate, reply rate, spam complaints, and unsubscribes — to score each sender. A spam complaint rate above 0.10% is enough to trigger filtering at Gmail. New sending domains must warm up gradually: starting at a few hundred emails per day and doubling weekly over 4–6 weeks before reaching full volume.
Running email deliverability for Biotech & Pharma with CoMo
CoMo's agents apply email deliverability across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Email Deliverability for Biotech & Pharma — common questions
What's the difference between delivery rate and deliverability?
Delivery rate measures the percentage of emails not bounced — accepted by the receiving server. Deliverability (or inbox placement rate) measures whether accepted emails reached the inbox versus spam or promotions folders. A 99% delivery rate and a 60% inbox placement rate can coexist, meaning 40% of 'delivered' email is never seen. Inbox placement is the metric that actually predicts revenue impact.
How does email deliverability differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.